These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 1267559)

  • 1. Factor IX deficiency in Gaucher disease. An in vitro phenomenon.
    Boklan BF; Sawitsky A
    Arch Intern Med; 1976 Apr; 136(4):489-92. PubMed ID: 1267559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factor IX Zutphen. A genetic variant of blood coagulation factor IX with an abnormally high molecular weight.
    Bertina RM; Van Der Linden IK
    J Lab Clin Med; 1982 Nov; 100(5):695-704. PubMed ID: 7130828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Non-activated and activated prothrombin complex concentrates, Proplex and Feiba, in the treatment of a hemophilia B patient with high titer inhibitor against factor IX].
    Niiya K; Hirose S; Taguchi H; Miyoshi I
    Rinsho Ketsueki; 1985 Jun; 26(6):980-4. PubMed ID: 3877825
    [No Abstract]   [Full Text] [Related]  

  • 4. Myocardial infarction during factor IX infusion in hemophilia B: case report and review of the literature.
    Najaf SM; Malik A; Quraishi AU; Kazmi K; Kakepoto GN
    Ann Hematol; 2004 Sep; 83(9):604-7. PubMed ID: 15205916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new drug form of blood coagulation factor IX: red blood cell-entrapped factor IX.
    Sinauridze EI; Vuimo TA; Kulikova EV; Shmyrev II; Ataullakhanov FI
    Med Sci Monit; 2010 Oct; 16(10):PI19-26. PubMed ID: 20885362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgical operation in hemophilia B. Use of factor IX concentrate.
    Kasper CK
    Calif Med; 1970 Jul; 113(1):4-8. PubMed ID: 5520728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquired factor IX inhibitor in a patient with Christmas disease: case report.
    Riyat MS; Kasili EG; Omondi BE
    East Afr Med J; 1984 Feb; 61(2):159-62. PubMed ID: 6468323
    [No Abstract]   [Full Text] [Related]  

  • 8. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.
    Björkman S; Folkesson A; Berntorp E
    Haemophilia; 2007 Jan; 13(1):2-8. PubMed ID: 17212717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factor IX-inhibitors. Report of two cases and a study of the biological, chemical and immunological properties of the inhibitors.
    Lechner K
    Thromb Diath Haemorrh; 1971 Jun; 25(3):447-59. PubMed ID: 5561957
    [No Abstract]   [Full Text] [Related]  

  • 10. Purification and properties of an abnormal blood coagulation factor IX (factor IXBm)/kinetics of its inhibition of factor X activation by factor VII and bovine tissue factor.
    Osterud B; Kasper CK; Lavine KK; Prodanos C; Rapaport SI
    Thromb Haemost; 1981 Feb; 45(1):55-9. PubMed ID: 7245126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate.
    Goudemand J; Peynet J; Chambost H; Négrier C; Briquel ME; Claeyssens S; Derlon-Borel A; Guérois C; Caron C; Scherrmann JM; Debray M; Bridey F
    Thromb Haemost; 1998 Dec; 80(6):919-24. PubMed ID: 9869161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orthotopic liver transplantation totally corrects factor IX deficiency in hemophilia B.
    Merion RM; Delius RE; Campbell DA; Turcotte JG
    Surgery; 1988 Nov; 104(5):929-31. PubMed ID: 3055399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune reactive factor IX in acquired factor IX deficiency.
    Lechner K
    Thromb Diath Haemorrh; 1972 Feb; 27(1):19-24. PubMed ID: 5033668
    [No Abstract]   [Full Text] [Related]  

  • 14. Time dependent factor IX inhibitor.
    Sarode R; Chauhan AP; Joseph M; Marwaha N; Sharma SK; Dash S
    Thromb Haemost; 1989 Dec; 62(4):1151. PubMed ID: 2559489
    [No Abstract]   [Full Text] [Related]  

  • 15. Biochemical and in vivo properties of high purity factor IX concentrates.
    Berntorp E; Björkman S; Carlsson M; Lethagen S; Nilsson IM
    Thromb Haemost; 1993 Nov; 70(5):768-73. PubMed ID: 8128433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Use of 2 preparations of factor IX concentrate in the treatment of a patient with hemophilia B].
    den Ottolander GJ
    Ned Tijdschr Geneeskd; 1972 Jul; 116(30):1278-82. PubMed ID: 5041298
    [No Abstract]   [Full Text] [Related]  

  • 17. Incidence of factor IX inhibitor development in severe haemophilia B patients treated with only one brand of high purity plasma derived factor IX concentrate.
    Parquet A; Laurian Y; Rothschild C; Navarro R; Guérois C; Gay V; Durin A; Peynet J; Sultan Y
    Thromb Haemost; 1999 Oct; 82(4):1247-9. PubMed ID: 10544907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of recombinant factor IX and thromboelastography in a patient with hemophilia B undergoing liver transplantation: a case report.
    De Pietri L; Masetti M; Montalti R; Begliomini B; Reggiani A; Barbieri E; Biagioni E; Marietta M; Romano A; Pasetto A; Gerunda GE
    Transplant Proc; 2008; 40(6):2077-9. PubMed ID: 18675136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombogenicity associated with factor IX complex concentrates.
    Lusher JM
    Semin Hematol; 1991 Jul; 28(3 Suppl 6):3-5. PubMed ID: 1780767
    [No Abstract]   [Full Text] [Related]  

  • 20. Factor IX alloantibodies shorten the bovine thromboplastin coagulation time of normal human plasma.
    Orstavik KH
    Thromb Haemost; 1981 Dec; 46(4):684-6. PubMed ID: 7330818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.